The CEO Diary with Fexingo · 2026-07-07 · 10 min
In this episode of The CEO Diary, Lucas and Luna explore how Anne Wojcicki built 23andMe from a startup selling $99 DNA tests to a publicly traded biotech company. They focus on the pivotal moment in 2013 when the FDA ordered 23andMe to stop selling its health reports, and how Wojcicki navigated the regulatory storm, kept the company alive, and eventually won FDA approval. The hosts discuss the strategic pivot to drug development, the controversial SPAC merger, and the tensions between consumer genetics and medical regulation. A case study in regulatory grit and long-term vision. #AnneWojcicki #23andMe #ConsumerGenetics #FDA #Regulatory #Biotech #SPAC #DirectToConsumer #DNA #HealthTech #Entrepreneurship #CEO #Leadership #Business #Startup #FexingoBusiness #BusinessPodcast #TheCEODiary Keep every episode free: buymeacoffee.com/fexingo
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
How Jorgen Vig Knudstorp Saved LEGO from the Brick52 / 100How Indra Nooyi Remade PepsiCo for the Long Term70 / 100How Pixar Saved Itself from Disney and Then Saved Disney73 / 100How Ford CEO Jim Farley Bet the Company on EVs with a Fleet of Mustangs76 / 100
How Nvidia Reinvented Its Business Model Twice65 / 100
